~~<i id='80113A01D6'><strike id='80113A01D6'><tt id='80113A01D6'><pre id='80113A01D6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：fashion 2025-08-12 06:45:24 - browse：51124

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Chan Zuckerberg Biohub Chicago to focus on inflammation

focus

knowledge

hotspot

knowledge

hotspot

leisure time

PresidentJoeBidenEliseAmendola/APWASHINGTON—ThelatestphaseofPresidentBiden’sCancerMoonshotinitiative

WSS

FDA rejects Alnylam's heart disease treatment over insufficient data

A new nitrogen execution bill also undermines medical licensing

Medicare inequities exacerbate Puerto Rico’s health disparities

When women are denied an abortion, their children fare worse than peers

Ed Silverman on new gene therapies, biosimilars, coffee, and more

NIH study of ME/CFS points to clear biological hallmarks

hotspot

Wikipedia

focus

Continuity nursing helped my family in our darkest PICU moments

What to expect at HLTH 2023, the health care industry conference

In age of alternative facts, a scholarly course on calling out crap

Liquid biopsy for lung cancer is launched by Delfi

Duchenne breakthrough therapy leaves behind pioneering families

Alabama IVF ruling threatens families facing fatal genetic disease

Guidelines to prevent youth baseball injuries need more muscle

A solution to the after

Duchenne breakthrough therapy leaves behind pioneering families

A solution to the after

knowledge

Colorectal cancer study finds potential in overlooked immune cell

Dario to buy mental health app maker Twill in cash and stock deal

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

A virus, fished out of a lake, may have saved a man’s life

Liquid biopsy for lung cancer is launched by Delfi

Chan Zuckerberg Biohub Chicago to focus on inflammation

hotspot

knowledge

hotspot

leisure time